CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
Because the activity of CC-4047 addresses numerous mechanisms of carcinoma growth inhibition
- including, but not limited to anti-angiogenesis - CC-4047 has been selected for development
as part of induction chemotherapy regimens for solid tumors. This study in pancreatic cancer
is designed to determine the appropriate CC-4047 dose and regimen in combination with
gemcitabine.